The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.
 
Mitchell Parma
No Relationships to Disclose
 
Eric Singhi
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Janssen; Lilly; Novocure; Regeneron
 
Luisa Maren Solis
Other Relationship - Travel support for participation in 10x Genomic Pathology Day event and participation in NanoString Roadshow event, both unrelated to this work.
(OPTIONAL) Uncompensated Relationships - Travel support for participation in 10x Genomic Pathology Day event and participation in NanoString Roadshow event, both unrelated to this work.
 
Wei-Lien Wang
No Relationships to Disclose
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline; InSightec; Lyell Immunopharma; Regeneron
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst); verismo (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - Hengenix; Nanobiotix (Inst)
 
Maria Franco-Vega
Consulting or Advisory Role - GlaxoSmithKline (I); Shattuck Labs (I)
Research Funding - Adaptimmune (I); Bristol-Myers Squibb (I); Genentech/Roche (I); GlaxoSmithKline (I); Jounce Therapeutics (I); Lilly (I); Merck (I); Nektar (I); Novartis (I); Shattuck Labs (I)
 
Alexa Halliday
No Relationships to Disclose
 
Joshua Jacome
No Relationships to Disclose
 
Jianjun Zhang
Honoraria - BeiGene; CancerNet; Geneplus; Geneplus; Hengrui Medicine; Innovent Biologics; innovent biologics; Innovent Biologics; Origimed; Roche; Roche China; Sino-USA Biomedical Platform; Suzhou Medical Association; Takeda; Varian Medical Systems; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Hunan Cancer Hospital; Johnson & Johnson/Janssen; Novartis
Research Funding - Helius; Merck; Novartis; Summit Therapeutics
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Lauren Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Novartis; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas (Priority date: 3/3/2021); Molecular subtyping of small cell lung cancer to predict therapeutic responses (US Patent No.: 11,732,306; Priority Date 9/3/2019; Issue Date 8/22/2023)
 
Carl Gay
Honoraria - American Society for Radiation Oncology; Aptitude Health; Daiichi Sankyo Nordics; DAVA Pharmaceuticals; Peerview; Physicans' Education Resource; Targeted Oncology
Consulting or Advisory Role - Abdera Therapeutics; Amgen; AstraZeneca; Catalyst Pharmaceuticals; G1 Therapeutics; Jazz Pharmaceuticals; Monte Rosa Therapeutics; Pharmerit
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - US-20240011103-A1 MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES
Travel, Accommodations, Expenses - American Society for Radiation Oncology; AstraZeneca; Dava Oncology; ESMO; IASLC; MJH Live Events; Roche/Genentech
 
Bingnan Zhang
Honoraria - Dava Oncology
Consulting or Advisory Role - Abdera Thereapeutics